Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HS-20090 vs Xgeva Pharmacokinetics in Healthy Adults
NCT05777109Phase 1Unknown
- Sponsor
- Hansoh Pharmaceutical Group
- Start
- Apr 2023
- Primary completion
- Apr 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of HS-20090 in bone metastases and Giant Cell Tumor of Bone (GCTB) (2 arms), sponsored by Hansoh Pharmaceutical Group. Primary endpoints: Area Under the Serum Concentration-Time Curve from Time Zero to Infinity at 155 days and Maximum Observed Serum Concentration at 155 days. Status: unknown.
02
Drugs
HS-20090
03
Conditions
bone metastasesGiant Cell Tumor of Bone (GCTB)
Beyond the preview
Go deeper on NCT05777109.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05777109.